AstraZeneca showcases strength of hematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022CALQUENCE real-world evidence and long-term follow-up data, as well as research collaborations, will reinforce efficacy and safety across B-cell malignanciesEarly clinic...
View pipeline Learn about our cell therapy ambition The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres Sustainability at AstraZeneca Corporate Press Release Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cance...
AstraZenecais strengthening its oncology pipeline with theacquisitionof TeneoTwo, which has an ongoing Phase I trial in relapsed and refractory B-cell non-Hodgkin lymphoma, in a deal valued at up to $1.27 billion. The transaction, expected to close in the third quarter of this year, includes...
Ruud Dobber, Ph.D, Executive Vice President and President, BioPharmaceuticals Business Unit, AstraZeneca, said: “Our broad pipeline and portfolio of inhaled and biologic medicines are the cornerstone of our bold ambition to ...
juncture in its evolution,” said Dr. Kaplan. “I look forward to working with the team to strengthen key areas of the business, positioning the Company for sustained success. Our commitment to advancing the organization will give us the potential to develop a pipeline of transformative therapies...
Thank you, Andy. Hello, everyone, and welcome to this half-year call. So if we move to Slide 5 please, we continue to deliver through the first half of 2022 both in terms of commercial performance as well as moving our pipeline forward. Total revenue increased 48% versus prior year to...
Since 2005, AstraZeneca has achieved an almost six-fold improvement in the proportion of its pipeline molecules that have advanced from preclinical investigation to completion of Phase III clinical trials - from 4% to 23%. This improvement moves AstraZeneca well above the...
Sumitomo Pharma is a biopharmaceutical company focused on developing therapeutic and scientific breakthroughs. The company's main offerings include the development of novel cancer therapeutics and a robust pipeline of treatments aimed at addressing unmet clinical needs in oncology. Sumitomo Pharma was former...
A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant ...
NI006, an ATTR depleter, adds a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies focused on amyloidosis and strengthens our broader commitment to addressing cardiomyopathies that can lead to heart ...